What is Leerink Partnrs’ Estimate for OKUR FY2024 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Equities researchers at Leerink Partnrs issued their FY2024 earnings estimates for OnKure Therapeutics in a report released on Thursday, December 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($3.89) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q4 2024 earnings at ($1.10) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.65) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.13).

Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Friday, November 8th. Oppenheimer started coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price target for the company. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th. Finally, Leerink Partners began coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 target price on the stock. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and an average target price of $36.00.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $15.00 on Monday. OnKure Therapeutics has a fifty-two week low of $9.80 and a fifty-two week high of $77.60. The stock has a market capitalization of $50.15 million, a price-to-earnings ratio of -1.23 and a beta of 0.14. The company’s 50 day moving average is $16.73.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.